Cannabinoid reference entry

THCV

THCV has its own structure and its own evidence

THCV is tetrahydrocannabivarin, a cannabinoid related to THC but chemically distinct. The V refers to a different side-chain structure. That distinction matters when a paper studies delta-8-THCV and a label or discussion refers to delta-9-THCV. The Home Office includes THC-V among controlled cannabinoids in its factsheet, so a THCV entry is not legal clearance.

A small diabetes pilot produced mixed results

A double-blind randomised pilot trial studied THCV in adults with non-insulin-treated type 2 diabetes. The THCV group showed changes in fasting glucose and selected metabolic measures, while the primary HDL outcome was unaffected. This was a small study with a defined question and preparation. It did not establish a general glucose, weight or appetite treatment effect, and it did not test a cannabis product as a whole.

Delta-8-THCV is not interchangeable by default

A separate 2023 human study used a dose-ranging, placebo-controlled design to examine acute effects and safety of oral delta-8-THCV in healthy participants. It was not a chronic patient study. Its findings should not be presented as evidence for delta-9-THCV without addressing the isomer difference.

Laboratory assays have also tested THCV with other cannabinoids at transient receptor potential channels and endocannabinoid enzymes. Those results are assay findings, not patient outcomes.

What the label can tell you

THCV on a laboratory report is a composition result. Product status depends on the whole preparation, not on one THCV percentage. The figure cannot provide legal clearance, a weight or appetite prediction, or a reason to choose a product. The MCPH cannabinoid reference keeps the related names together.

Related conditions

Sources

For broader terminology, browse the UK Medical Cannabis Glossary.

Read next

Other cannabinoid entries